Most patients report a reduction in redness and itching within 3-5 days of consistent application. Visible thinning of plaques or scaling may take 1-2 weeks, depending on the severity of the condition.
Fluocinolone acetonide is a potent steroid, and the facial skin, especially around the eyes, is more susceptible to thinning and irritation. Routine use on these areas is discouraged unless a dermatologist specifically prescribes it and monitors the treatment closely.
Synalar is supplied as a cream, which is water-based and generally less greasy than an ointment. Creams are suitable for moist or weepy lesions, while ointments provide a more occlusive barrier and are preferred for very dry, scaly patches. The active concentration (0.025 %) remains the same.
Potent topical corticosteroids are usually avoided during pregnancy and lactation, particularly on large skin areas, because of a theoretical risk of fetal growth restriction or neonatal adrenal suppression. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their clinician.
The product is not licensed for routine use in children under 12 years. In special circumstances, a paediatric dermatologist may prescribe a lower-potency steroid. Off-label use in children should only occur under specialist supervision.
Apply the missed dose as soon as you remember, unless the next scheduled dose is within a few hours. In that case, skip the missed application and continue with the regular schedule; do not double the amount.
Prolonged application of potent steroids like fluocinolone acetonide can lead to skin atrophy, including thinning, visible blood vessels, and striae, especially when used under occlusion or on large areas. Limiting treatment duration and following tapering instructions reduces this risk.
Empty tubes should be returned to a pharmacy collection point for safe disposal, or placed in the household waste if the local council advises that method. Do not flush the product down the toilet.
Systemic absorption from topical use is generally low, but large-area or prolonged treatment may raise blood glucose modestly in susceptible individuals. Diabetic patients should monitor their glucose more closely while using the medication and report any significant changes to their healthcare provider.
Allergic contact dermatitis to fluocinolone acetonide or any excipient in the cream is rare but possible. Symptoms include intense itching, redness, swelling, or blistering at the application site. If these occur, stop using the product and seek medical evaluation.
Therapeutic class: Skin-care (topical corticosteroid) Active ingredient: Fluocinolone acetonide Formulation: 0.025 % cream in a 30 g tube (prescription-only medicine, POM) Regulatory authority: Medicines and Healthcare products Regulatory Agency (MHRA)
Synalar delivers fluocinolone acetonide, a synthetic glucocorticoid, to the skin. It is supplied as a cream in a tube and is intended for short-term treatment of inflammatory skin disorders. Below is an evidence-based guide for patients and health-care professionals in the United Kingdom.
Fluocinolone acetonide belongs to the corticosteroid family. After the cream is applied, the drug penetrates the epidermis and binds to intracellular glucocorticoid receptors. This binding alters gene transcription, leading to:
These actions collectively calm the inflammatory response that characterises conditions such as eczema or psoriasis. Onset of symptom relief is usually observed within a few days, while the peak anti-inflammatory effect occurs after several days of consistent use. Because the medication is applied locally, systemic exposure is minimal for most patients, although absorption can increase when large body areas are treated, the skin is broken, or an occlusive dressing is used.
Synalar is authorised by the MHRA for the following indications:
These approvals are based on clinical trials that demonstrated significant improvement in lesion severity compared with placebo or lower-potency steroids. The medication is intended for adult patients; use in children under 12 years is considered off-label and requires specialist supervision.
Any off-label application must be judged by a qualified clinician, weighing potential benefits against the risk of adverse effects.
Absolute contraindications
Relative contraindications
Patients with uncontrolled diabetes, hypertension, or immune suppression should discuss use with a healthcare professional, as systemic absorption, though low, could modestly affect disease control when large areas are treated.
If irritation persists beyond a few days, the patient should seek medical advice.
Any sudden worsening of skin condition, unexplained bruising, or signs of systemic corticosteroid effects (e.g., rapid weight gain, mood changes) warrant immediate medical attention.
Topical fluocinolone acetonide has minimal systemic drug-interaction potential. However:
Patients should disclose all prescription, over-the-counter, and herbal products to their prescriber.
Driving or operating machinery is not impaired by Synalar.
Missed dose: Apply the missed dose as soon as remembered, unless the next scheduled dose is approaching. Do not double the amount.
Overdose: Signs include widespread skin thinning, easy bruising, or systemic corticosteroid symptoms (e.g., high blood pressure, hyperglycaemia). Seek urgent medical care; treatment focuses on supportive care and gradual tapering if systemic effects are present.
Discontinuation: For short-term courses (≤2 weeks), abrupt cessation is acceptable. Longer therapy should be tapered under medical supervision to reduce rebound inflammation and minimise HPA-axis suppression.
Patients should contact their healthcare provider if the condition worsens, new lesions appear, or side effects become bothersome.
This article provides educational information about Synalar (fluocinolone acetonide 0.025 % cream) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
